Lexaria Bioscience Corp (LEXX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.75 is considered Undervalued compared with the five-year average of -3.42. The fair price of Lexaria Bioscience Corp (LEXX) is between 0.90 to 2.39 according to relative valuation method. Compared to the current price of 0.71 USD , Lexaria Bioscience Corp By Undervalued By 21.47%.

Relative Value

Fair Zone

0.90-2.39

Current Price：0.71

21.47%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lexaria Bioscience Corp (LEXX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lexaria Bioscience Corp (LEXX) has a current Price-to-Book (P/B) ratio of 4.28. Compared to its 3-year average P/B ratio of 3.83, the current P/B ratio is approximately 11.66% higher. Relative to its 5-year average P/B ratio of 3.19, the current P/B ratio is about 33.98% higher. Lexaria Bioscience Corp (LEXX) has a Forward Free Cash Flow (FCF) yield of approximately -64.36%. Compared to its 3-year average FCF yield of -37.53%, the current FCF yield is approximately 71.49% lower. Relative to its 5-year average FCF yield of -30.93%, the current FCF yield is about 108.09% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LEXX competitors is 49.82, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX.O) exhibits a P/S ratio of 20.75, which is -58.36% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LEXX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LEXX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LEXX currently overvalued or undervalued?

Lexaria Bioscience Corp (LEXX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.75 is considered Undervalued compared with the five-year average of -3.42. The fair price of Lexaria Bioscience Corp (LEXX) is between 0.90 to 2.39 according to relative valuation method. Compared to the current price of 0.71 USD, Lexaria Bioscience Corp is Undervalued By 21.47%.

What is Lexaria Bioscience Corp (LEXX) fair value?

LEXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lexaria Bioscience Corp (LEXX) is between 0.90 to 2.39 according to relative valuation method.

How does LEXX's valuation metrics compare to the industry average?

The average P/S ratio for LEXX's competitors is 49.82, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX) exhibits a P/S ratio of 20.75, which is -58.36% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Lexaria Bioscience Corp (LEXX) as of Mar 03 2026?

As of Mar 03 2026, Lexaria Bioscience Corp (LEXX) has a P/B ratio of 4.28. This indicates that the market values LEXX at 4.28 times its book value.

What is the current FCF Yield for Lexaria Bioscience Corp (LEXX) as of Mar 03 2026?

As of Mar 03 2026, Lexaria Bioscience Corp (LEXX) has a FCF Yield of -64.36%. This means that for every dollar of Lexaria Bioscience Corp's market capitalization, the company generates -64.36 cents in free cash flow.

What is the current Forward P/E ratio for Lexaria Bioscience Corp (LEXX) as of Mar 03 2026?

As of Mar 03 2026, Lexaria Bioscience Corp (LEXX) has a Forward P/E ratio of -1.64. This means the market is willing to pay $-1.64 for every dollar of Lexaria Bioscience Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lexaria Bioscience Corp (LEXX) as of Mar 03 2026?

As of Mar 03 2026, Lexaria Bioscience Corp (LEXX) has a Forward P/S ratio of 20.75. This means the market is valuing LEXX at $20.75 for every dollar of expected revenue over the next 12 months.

LEXX Valuation